Current and Emerging Clinical Treatment in Mitochondrial Disease.

Primary mitochondrial disease (PMD) is a group of complex genetic disorders that arise due to pathogenic variants in nuclear or mitochondrial genomes. Although PMD is one of the most prevalent inborn errors of metabolism, it often exhibits marked phenotypic variation and can therefore be difficult to recognise. Current treatment for PMD revolves around supportive and preventive approaches, with few disease-specific therapies available. However, over the last decade there has been considerable progress in our understanding of both the genetics and pathophysiology of PMD. This has resulted in the development of a plethora of new pharmacological and non-pharmacological therapies at varying stages of development. Many of these therapies are currently undergoing clinical trials. This review summarises the latest emerging therapies that may become mainstream treatment in the coming years. It is distinct from other recent reviews in the field by comprehensively addressing both pharmacological non-pharmacological therapy from both a bench and a bedside perspective. We highlight the current and developing therapeutic landscape in novel pharmacological treatment, dietary supplementation, exercise training, device use, mitochondrial donation, tissue replacement gene therapy, hypoxic therapy and mitochondrial base editing.

Key Points

Introduction

Primary mitochondrial diseases (PMDs) are clinically diverse metabolic disorders arising from pathogenic variants in genes that affect mitochondrial function [1]. These pathogenic variants generally impair mitochondrial structure and function by disrupting multiple mitochondrial processes such as oxidative phosphorylation, ion transport across the mitochondrial membrane and mitochondrial fission and fusion [2]. PMDs are caused by a vast spectrum of pathogenic variants in both nuclear (nDNA) and mitochondrial DNA (mtDNA) [3]. mtDNA is a 16.5 Kb, double-stranded, circular molecule of DNA that is distinct from nDNA and present in multiple copies throughout the cell’s cytoplasm. Typically, individuals have only one mtDNA genotype (inherited maternally), and all mitochondrial genomes are genetically identical. However, wild-type and mutated maternal alleles can coexist, a situation known as heteroplasmy [3]. When a tissue-specific threshold is exceeded, the severity of symptoms in patients with PMD is often directly associated with the level of heteroplasmy in affected tissues [4]. Nuclear DNA (nDNA) by contrast, is inherited from both parents and resides in strands in a cell’s nucleus. nDNA is also substantially larger in size (3 billon base pairs with 20,000 known genes). PMDs are clinically challenging to diagnose and treat as they are highly heterogeneous regardless of genetic aetiology [4]. PMD can affect almost any organ at any age. However, with the exception of Leber’s Hereditary Optic Neuropathy (LHON), PMDs rarely causes disease isolated to a single tissue. Indeed there are a number of well characterised syndromic presentations of PMD (and perhaps more cases with non-syndromic multiple organ involvement) that present throughout the age spectrum [5]. At present, the prevalence of PMD in the UK population is estimated at 1 in 4,300 (adults and children) [6]. However, this prevalence rate can vary substantially between different ethnic populations [7]. Current treatment of PMD involves symptomatic management with a limited therapeutic arsenal of specific disease-modifying therapies [8, 9]. However, in recent years there has been a plethora of emerging pharmacological and non-pharmacological treatment [8, 9]. The purpose of this review is to summarise the current and emerging therapeutic landscape in PMD. The article is distinguishable from other recent reviews in the field by focusing on many of the non-pharmacological treatments in development, from both a basic science and a clinical perspective.

Current Therapy

A common challenge faced in rare genetic diseases such as PMD is a historic paucity of disease-specific treatment [8-10]. The management of PMD conditions remains a poorly researched area and there is little expert advice available for the treatment of specific aspects of mitochondrial disease [8-10]. The involvement of several organs can pose additional patient management challenges for clinicians [8-10]. The current mainstay of treatment involves the optimisation of conventional organ-specific care and regular health surveillance for potential complications of PMD [8-10]. There have been multiple attempts to standardise the diagnosis and treatment of PMD both nationally and internationally [11-13]. Several guidelines and consensus recommendations have been generated by clinical experts from the UK (https://www.newcastle-mitochondria.com/) and the USA, with the aim of providing guidance to healthcare professionals in the management of patients with mitochondrial disease [11-13].

Although few in number, some disease-specific therapies for PMD are available [8-10]. For instance, mitochondrial disease patients with a cofactor deficiency (i.e. thiamine, riboflavin, biotin or niacin) respond to cofactor treatment [14, 15]. The genes implicated in these genetic cofactor deficiencies are summarised in Table 1 [16-20]. Beyond these deficiency syndromes, there is limited clinical use of disease-specific treatment. Controversially in 2015, the European Medicines Agency (EMA) licenced the synthetic antioxidant idebenone for the treatment of LHON in patients over 12 years of age [22]. However, the UK-based National Institute for Health and Care Excellence (NICE) prevented the provision of idebenone through the NHS, given the expense of the drug and low-quality evidence for its efficacy (further discussed in section 5.2) [21]. Long-term survival in patients with mitochondrial neurogastrointestinal encephalomyopathy has been increased by allogeneic hematopoietic stem cell transplantation [22]. While not universally accepted, there is emerging evidence that multiple agents can prevent and treat stroke-like episodes in MELAS, with L-arginine now recommended in North American (Mitochondrial Medicine Society) consensus guidelines [11]. Additionally, taurine supplementation has been shown in a small phase 3 randomised controlled trial (RCT) to prevent stroke-like episodes in MELAS [23]. However, further studies in larger patient cohorts are required before taurine supplementation can be recommended.

Table 1

Summary of the genes implicated in genetic cofactor deficiencies

Mutated gene	Function	References
Thiamine transporter 2	Thiamine transporter	[16]
Biotinidase	Biotinidase enzyme	[17]
Decaprenyl Diphosphate Synthase Subunit 2	CoQ10 synthesise enzyme	[16]
Pyruvate Dehydrogenase E1 Subunit Alpha 1	Subunit of PDH	[18]
Thiamin Pyrophosphokinase 1	Thiamine metabolism	[19]
Acyl-CoA dehydrogenase family member 9	Subunit of complex I	[20]

CoQ coenzyme Q10, PDH pyruvate dehydrogenase

Emerging Therapies

In recent years there has been an increase in the development of novel pharmacological and non-pharmacological treatment [8-10]. To review this landscape, we searched the MEDLINE database via PubMed, using the following keywords: ‘mitochondrial disorder(s)’, ‘mitochondrial disease(s)’, ‘treatment(s)’ and ‘therapy’ (with no search limits). We supplemented this review by searchingClinicalTrials.gov for ‘mitochondrial disorders’ (up until 10 August 2020) (with no search limits). From our search, we discovered that there has been an exponential growth in the number of clinical trials registered to start since 2000 (Fig. 1), with a total of 232 studies conducted (of which 182 were interventional). The most common subcategories identified in the treatment of PMD included pharmacological (N = 105 trials) and dietary supplements (N = 15 trials) (Fig. 1, Online Supplementary Material (OSM)).

Fig. 1

The cumulative number and subcategories of clinical trials registered at ClinicalTrials.gov using the search term ‘mitochondrial disorders’ up until 10/08/2020.

Emerging Pharmacological Treatment

The translation of modern genomic technology into clinical practice and research has facilitated major advances in the development of treatment for rare genetic diseases [24]. Accordingly, there has been an exponential expansion in the development of novel pharmacological treatment for PMD (Table 2), facilitated by regulatory and financial incentives aimed at increasing investment in orphan drug discovery [8–10, 25]. Many developing therapies may also be of potential use in a range of other neurological diseases [26]. It is encouraging that many of these newly developed compounds are now undergoing clinical trials in humans. To date, 131 clinical trials involving a pharmacological intervention in the treatment of mitochondrial disease have been registered publicly on Clinicaltrials.gov (Fig. 1). The specific preclinical mechanisms of these newly developed therapies can be categorised into four major groups: (1) increasing the cellular concentration of mitochondria and nicotinamide adenine dinucleotide+ (NAD+), (2) protecting mitochondria from damage, (3) improving mitochondrial function and (4) restoring mtDNA homeostasis [27-30].

Table 2

Summary of the historic and current disease specific pharmacological therapeutic landscape for in mitochondrial disease.

Disease(s)/syndrome(s) investigated	Pharmacological agent	Trial phase	Description	N	Most recent update	Status/result	Trial ID
Childhood PMD	Cysteamine	2	Safety, tolerability, efficacy, pharmacokinetics and pharmacodynamics	36	2017	Terminated (lack of effect)	NCT02023866
	EPI-743	1/2	Crossover trial to investigate efficacy	20	2020	Completed	NCT01642056
Leigh and Leigh-like	ABI-009	2a	Safety, tolerability and efficacy	32	2020	Not yet recruiting	NCT03747328
	EPI-743	2	Safety, tolerability and efficacy	30	2020	Active, not recruiting	NCT02352896
	KL1333	1	Safety	30 (C)	2016	Completed	NCT02544217
LHON	Elamipretide	2	Safety, tolerability and efficacy	12	2019	Completed	NCT02693119
	Idebenone	4	Efficacy (long term follow-up)	250	2019	Active, not recruiting	NCT02774005
		4	Safety (long term follow-up)	250	2020	Active, not recruiting	NCT02771379
		4	Expanded access	NA	2020	Available	NCT04381091
		2	Safety, tolerability and efficacy	85	2013	Completed	NCT00747487
	KL1333	1	Safety	30 (C)	2016	Completed	NCT02544217
m.3243A<G	Acipimox	2a/2b	Adaptive design; single centre	80-120	2020	Recruiting	ISRCTN12895613
	KL1333	1	Safety	30 (C)	2016	Completed	NCT02544217
ME	KH176	2	Safety, tolerability and efficacy	20 (C)	2018	Completed	NCT02909400
	KL1333	2	Safety, tolerability and efficacy	27 (C)	2020	Recruiting	NCT04165239
MELAS	Dichloroacetic acid	2	Treatment	35	2005	Terminated (peripheral nerve toxicity)	NCT00068913
	Idebenone	2	Treatment	27	2016	Completed	NCT00887562
	KH176	2	Safety, tolerability and efficacy	20 (C)	2018	Completed	NCT02909400
	KL1333	1	Safety	30 (C)	2016	Completed	NCT02544217
		2	Safety, tolerability and efficacy	27 (C)	2020	Recruiting	NCT04165239
MIDD	KH176	2	Safety, tolerability and efficacy	20 (C)	2018	Completed	NCT02909400
	KL1333	1a/1b	Safety, tolerability, pharmacokinetics and pharmacodynamics	72 (C)	2019	Recruiting	NCT03888716
mDNA depletion	Thymidine and deoxycytidine	1/2	Safety, tolerability and efficacy	20	2019	Enrolling by invitation	NCT03639701
Mitochondrial respiratory chain deficiencies	EPI-743	2	Palliative expanded access protocol	94	2020	Active, not recruiting	NCT01370447
	KL1333	1a/1b	Safety, tolerability, pharmacokinetics and pharmacodynamics	72 (C)	2019	Recruiting	NCT03888716
Pearson	EPI-743	2	Safety, tolerability and efficacy	2	2018	Terminated	NCT02104336
PMD	Bezafibrate	2	Treatment	6	2017	Awaiting results	NCT02398201
	KL1333	2	Safety, tolerability and efficacy	27 (C)	2020	Recruiting	NCT04165239
	Elamipretide	2	Safety, tolerability and efficacy	36	2020	Terminated	NCT02976038
		2	Safety, tolerability and efficacy	30	2017	Completed	NCT02805790
		2	Prospective observational	215	2019	Completed	NCT03048617
	KH176	2	Safety, tolerability and efficacy	20 (C)	2018	Completed	NCT02909400
	KL1333	1	Safety	30 (C)	2016	Completed	NCT02544217
		1a/1b	Safety, tolerability, pharmacokinetics and pharmacodynamics	72 (C)	2019	Recruiting	NCT03888716
PMM	Elamipretide	3	Safety, tolerability and efficacy	218	2020	Failed (did not meet primary end-point)	NCT03323749
	KH176	2	Safety, tolerability and efficacy	20 (C)	2018	Completed	NCT02909400
	KL1333	2	Safety, tolerability and efficacy	27 (C)	2020	Recruiting	NCT04165239
		1a/1b	Safety, tolerability, pharmacokinetics and pharmacodynamics	72 (C)	2019	Recruiting	NCT03888716
	REN001	1	Safety	23	2020	Not reported	NCT03862846
	RTA 408	2	Safety, efficacy and pharmacodynamics	53	2018	Completed Results not reported	NCT02255422
PCDC	Dichloroacetic acid	3	Treatment	9	2020	Recruiting	NCT02616484

Recruiting trials as of August 2020 are indicated in bold. Please note some trials investigate therapy in multiple disorders

C combined clinical trial investigating multiple primary mitochondrial diseases, LHON Leber's hereditary optic neuropathy, ME myalgic encephalomyelitis, MELAS mitochondrial encephalopathy lactic acidosis and stroke-like episodes, N number of participants recruited lactic acidosis and stroke-like episodes, MIDD maternally inherited diabetes-deafness syndrome, PCDD pyruvate dehydrogenase complex deficiency, PMD primary mitochondrial disease, PMM primary mitochondrial myopathies

Increasing the Cellular Concentration of Mitochondrial NAD+ and Mitochondria

Numerous novel pharmacological agents have been developed that aim to increase the cellular concentration of NAD+ and the number of mitochondria [31]. NAD+ is an oxidising cofactor that accepts electrons in redox reactions [31]. This allows electrons to be carried from one reaction to another, a fundamental process required for oxidative metabolism [31]. Higher concentrations of both mitochondria and NAD+ in cells may increase oxidative phosphorylation in diseased tissue, ultimately improving symptoms and disease progression in PMD [31]. Acipimox, bezafibrate, omaveloxolone and REN001 aim to treat mitochondrial disease by increasing the cellular mitochondrial concentration. In contrast, KL1333 is purported to increase the cellular concentration of NAD+.

Acipimox (5-carboxyl-2-methyl pyrazine 1-oxide) is a niacin derivative and nicotinic acid analogue with activity as a hypolipidaemic agent [32-34]. The drug is currently used for the treatment of hyperlipidaemia in non- insulin-requiring diabetes mellitus [32-34]. Acipimox has been shown to have a direct effect on human skeletal muscle mitochondrial function in patients with diabetes [35]. Acipimox lowers plasma free fatty acids by inhibiting lipolysis through indirectly inhibiting hormone-sensitive lipase [36]. This in turn promotes an increase in NAD+, sirtuin 1 (SIRT1) activation and enhanced mitochondrial gene expression [37]. Although acipimox has a favourable side-effect profile, it can cause facial flushing, which may limit patient retention (and blinding) in clinical trials [32]. An ongoing double-blinded, placebo-controlled RCT of the efficacy of acipimox in patients with mitochondrial myopathy aims to repurpose acipimox as a potent stimulator of mitochondrial biogenesis.

Bezafibrate is a fibrate drug that increases mitochondrial biogenesis [38]. It was originally licensed in 1978 to treat hyperlipidaemia and therefore has long-term evidence of a favourable side-effect profile [39]. An open‐label, non‐randomised trial in patients with mitochondrial myopathy (m.3243A>G point pathogenic variant, n = 6) demonstrated that bezafibrate decreased the number of complex IV‐deficient muscle fibres and improved cardiac function, with no significant adverse effects reported [29]. However, this improvement was accompanied by an increase in serum biomarkers of PMD (e.g. GDF15 [growth and differentiation factor 15]), raising concerns about long-term treatment effects in patients with PMD [38]. A further phase 2 RCT is required to further ascertain the efficacy and safety of bezafibrate.

REN001, a selective and orally bioavailable peroxisome proliferator-activated receptor delta (PPARδ) agonist, is currently being trialled as a treatment for patients with fatty acid oxidation (FAO) disorders and mitochondrial myopathies [40]. This compound was previously used for prevention of respiratory failure and immobilisation-induced skeletal muscle atrophy [40]. PPARδ regulates genes involved in several cellular metabolic processes including glucose homeostasis, fatty acid synthesis and storage, and fatty acid mobilization and metabolism [41]. PPARδ is expressed in liver, skeletal muscle and adipose tissue [41]. In animal models, PPARδ increases the number of muscle fibres with high mitochondrial content and improves FAO [41]. The premise for treatment in patients with PMD is that this selective PPARδ agonist may ameliorate the cellular energy deficit via increasing the proportion of wild-type mtDNA [42]. The other potential benefits include increasing FAO and OXPHOS activity, thereby enhancing mitochondrial ATP-generating capacity and boosting mitochondrial biogenesis [59]. An open-label study to evaluate the tolerability of this drug over 12 weeks was paused due to the COVID-19 pandemic (NCT03862846).

Omaveloxolone is an oleanolic triterpenoid that prevents nuclear factor erythroid 2-related factor 2 (Nrf2) degradation, inhibiting the nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB) pro-inflammatory pathway [43]. This inhibition has been shown to improve oxidative phosphorylation and mitochondrial biogenesis in patients with mitochondrial myopathy (n = 53) [43]. A phase 2 double-blind, dose-ranging, placebo-controlled RCT of omaveloxolone in 53 patients with mitochondrial myopathy failed to meet its primary outcome (peak workload assessed via an incremental cycling exercise test) [44]. However, omaveloxolone treatment resulted in a lower heart rate and blood lactate level during a constant workload (submaximal) exercise test, suggesting some improvement in mitochondrial function [44]. Further clinical trials with methodical refinement may therefore be required to ascertain the efficacy of omaveloxolone.

KL1333 is a substrate for NAD(P)H:dehydrogenase [quinone]1, which produces nicotinamide adenine. KL1333 then transfers these electrons to the mitochondrial electron transport system, directly promoting ATP production [45]. The elevated level of NAD+ leads to the activation of mitochondrial biogenesis pathways SIRT1, 5’-adenosine monophosphate-activated protein kinase (AMPK) and peroxisome proliferator-activated receptor gamma coactivator 1-alpha (PGC-1α), thereby improving mitochondrial function [45]. Given these beneficial effects on mitochondrial function, a double-blinded, parallel-group, placebo-controlled, phase 1 RCT to assess the pharmacokinetics and pharmacodynamics of this compound in patients with PMD has recently been launched (NCT03056209).

Protecting Mitochondria from Damage

Protecting functioning mitochondria from damage that could ultimately reduce their ability to perform oxidative phosphorylation is an emerging mechanism for potential treatment [8-10]. There are multiple mechanisms to potentially protect mitochondria including increasing the production of endogenous antioxidants (cysteamine), reducing the production of toxic reactive oxygen species (ROS) (KH17 and elamipretide), and acting as a potent synthetic antioxidant to absorb free radicals before they damage mitochondria (EPI-743 and idebenone). ROS are reactive compounds that contain oxygen in its reduced chemically reactive form (O−2) [46]. These compounds are a by-product of normal metabolism of oxygen but during metabolic stress (e.g. during illness) ROS levels can dramatically increase, this process can damage proteins from intracellular organelles including mitochondria in a process known as oxidative stress [46]. Some compounds have also been designed with a dual mechanism. For example, KH176 protects mitochondria by acting as both a synthetic antioxidant and a redox modulator.

Cysteamine is a US Food and Drug Administration (FDA)-approved treatment for nephropathic cystinosis that has the potential to be repurposed for the treatment of PMD [47]. Its primary mechanism is to increase glutathione biosynthesis (a potent antioxidant). In vivo (C elegans and zebrafish) and in vitro (human fibroblast) experiments have shown that cysteamine improves mitochondrial function by protecting complex I and IV from damage [48]. However, a phase 2 open-label, dose-escalating study assessing the safety, tolerability and efficacy of cysteamine treatment in PMD (n = 36) was terminated due to a lack of efficacy, leaving the repurposing of cysteine in jeopardy (NCT02023866).

KH176 is a potent intracellular reduction-oxidation‐modulating compound developed to treat PMD [49]. The compound also acts as a synthetic antioxidant (removing oxidative stress). Through this duel mechanism, KH176 can reduce both ROS production and absorption. KH176 has demonstrated safety in a phase 1 trial [50]. A subsequent phase 2 double-blind, placebo-controlled, crossover RCT in 18 patients with m.3243A>G pathogenic variants demonstrated that the medication was safe and tolerated (KHENERGY Study) (NCT02909400) [51]. However, this study was exploratory, and therefore lacked any defined primary and secondary outcomes. A further phase 3 trial is currently being conducted to ascertain the efficacy and safety of KH176 (NCT02909400).

Elamipretide is a tetrapeptide that targets the mitochondria, stabilizing cardiolipin whilst reducing the production of ROS [52]. A phase 1/2 multicentre, double-blind, placebo-controlled RCT investigating elamipretide for the treatment of mitochondrial myopathy in 36 patients (MMPOWER study) demonstrated safety and efficacy (increase in 6-min walk test distance (6MWTD)) [53]. However, a follow-up phase 3 study (n = 218 patients) (MMPOWER-3, NCT03323749) did not meet its primary end-point (increase in 6MWTD), leaving the efficacy of elamipretide unclear.

EPI-743 (also known as vatiquinone) is a novel small-molecule catalytic, 2-electron transfer NAD(P)H quinone dehydrogenase 1 (NQO1) cofactor that decreases the production of intracellular glutathione [54]. The drug is a para-benzoquinone analogue of CoQ10 with up to 10,000 times its antioxidant potency [54]. A 2012 phase 2A open-label trial of EPI-743 for children with Leigh syndrome (n = 10) demonstrated a statistically significant objective neurological improvement in the Newcastle Paediatric Mitochondrial Disease Scale (NPMDS), with no significant drug-related adverse events [55]. Based on these results, further phase 1/2 clinical trials are currently being conducted (Table 2). EPI-743 has been used in randomized, double-blind, placebo-controlled clinical trials in children with Leigh syndrome (NCT01721733 and NCT02352896). Enrolled patients first participated in a 6-month placebo-controlled phase, which was followed by a 30-month extension phase to assess the long-term drug safety and impact on disease severity [56]. The results of this study were reported at the United Mitochondrial Disease Foundation Annual Meeting, Seattle, Washington, USA, 2016. However, despite evidence of EPI-743 reducing hospital admission, the study is yet to be published [56]. This highlights the need to publish trial results rapidly and transparently. Of note, the FDA recently granted approval for a study to investigate the safety and efficacy of the drug in 94 children with terminal genetically confirmed inherited respiratory chain diseases (NCT01370447). This study is scheduled to report in December 2021.

Idebenone is a short-chain hydrosoluble quinone synthetic analog of CoQ10 that acts as an electron carrier in the respiratory chain [57, 58]. The drug was originally developed to treat CoQ10 deficiency but was unsuccessful in this regard and has recently been repurposed and licensed to treat patients with LHON [59]. A double-blind, phase 2 RCT (RHODOS) demonstrated limited efficacy, whereby no significant difference in the primary outcome (visual acuity) was observed compared to placebo treatment [59]. However, subgroup analysis demonstrated an improvement in discordant visual acuity [59]. Two phase 4 clinical trials are currently being conducted to further understand the benefits of idebenone (NCT02774005 and NCT02771379) (Table 2). Further studies are also underway to investigate the efficacy of idebenone in other PMDs (Table 2). As previously mentioned, although idebenone has been licensed by the EMA, NICE recommended that it should not be available for prescription through the NHS in the UK [22]. This is a consequence of the high cost of treatment relative to the lack of robust evidence demonstrating efficacy. Additionally, NICE also cited a lack of long-term follow up in the original clinical trial. NICE also expressed additional concern at the exclusion of a patient from analysis resulting in a substantial demographic difference between the control and treatment group [22]. The current situation regarding the prescription of idebenone will likely be repeated in other emerging disease-specific treatments for PMD in the NHS and other public health systems worldwide. Orphan drugs in PMD have high development costs. When combined with the rarity of PMD, high drug prices are likely. Therefore, if the evidence for efficacy is not robust, NICE are unlikely to allow public prescription, and, in turn, prevent long-term follow-up studies that can elucidate efficacy.

Improving Mitochondrial Function

Various pharmacological agents have been developed that improve the efficiency of oxidative phosphorylation in diseased mitochondria as opposed to increasing their number [8-10]. ABI-009 and dichloroacetate are two medications from this class that are currently undergoing clinical trials.

ABI-009 (known as nab-sirolimus) is a nanoparticle undergoing phase 2a open-label trials evaluating safety, tolerability and efficacy in the treatment of Leigh or Leigh-like syndrome (NCT03747328). ABI-009 is composed of the antibiotic rapamycin bound to nanoparticle albumin. The compound is reported to improve mitochondrial function by increasing amino acid catabolism, reducing glycolysis [29]. The reduction in glycolytic intermediates increases mitochondrial oxidative phosphorylation by an unknown mechanism [29]. Preclinical evidence in a Leigh syndrome murine model has demonstrated that ABI-009 reduces neuroinflammation and the size of brains lesions, delaying the onset of neurological symptoms [29]. However, the validity of preclinical evidence is limited as the Leigh syndrome murine model reflects only one genotype (NDUFS4). This contrasts with Leigh syndrome in humans, which is caused by many different genetic variants involving both mtDNA and nDNA [60].

Dichloroacetate (DCA) is a drug that stimulates the pyruvate dehydrogenase (PDH) complex (a common site of pathological metabolic dysfunction) by altering its phosphorylation state and thus promoting complex stability [18]. Three clinical trials have been conducted for DCA in mitochondrial genetic disease [19, 61, 62]. Two of these trials showed an improvement in post-prandial and exercise blood lactate compared to placebo. However, these studies did not show any improvement in patient quality of life (assessed through global assessment of treatment efficacy scores) or aerobic metabolism function (assed through a 1-h treadmill test) [61, 62]. However, a third trial (conducted in older subjects) was terminated due to drug-associated neuropathy [19]. A phase 3 quadruple blinded RCT is currently being conducted to investigate the efficacy of DCA in pyruvate dehydrogenase complex deficiency (PDCD) (NCT02616484).

Restoring mtDNA Homeostasis

Loss of function pathogenic variants in the synthesis of mtDNA result in a reduction in mitochondrial oxidative phosphorylation. This results in numerous PMDs including mitochondrial depletion syndrome (MDS) and mitochondrial neurogastrointestinal encephalomyopathy (MNGIE), for which there is emerging pharmacological treatment.

In mitochondrial depletion syndrome (MDS), there is a reduction in the production of mtDNA. This is due to an autosomal recessive loss-of-function pathogenic variant, resulting in defective thymidine kinase 2 (TK2) activity. TK2 is a critical enzyme in mtDNA synthesis through its phosphorylation of precursor nucleosides (deoxycytidine and deoxythymidine). Pathogenic variants result in a reduced pool of deoxynucleoside triphosphates, which are required for mtDNA replication and maintenance. A retrospective analysis of 92 patients with genetically confirmed TK2 deficiency revealed three myopathic phenotypes with divergent survival: infantile-onset, childhood-onset and late-onset myopathies [63]. Oral supplementary deoxynucleoside administration is an emerging therapy in MDS that bypasses the defective enzymatic pathway [64, 65]. Preclinical evidence in murine models has demonstrated that deoxynucleoside treatment is both tolerable and effective in restoring mtDNA copy number and respiratory chain enzyme activity, resulting in a prolonged lifespan [65]. A combined phase 1/2 open-label compassionate-use study (n = 16) of oral deoxynucleoside to treat TK2-deficient patients demonstrated a favourable side-effect profile and improved survival and motor function [46]. A further combined phase 1/2 trial (n = 20 patients) is currently being conducted to expand on this work (NCT03639701).

MNGIE is an autosomal recessive disorder caused by loss-of-function pathogenic variants in the gene that encodes for thymidine phosphorylase (TYMP), a critical enzyme in mtDNA synthesis [66]. The disease presents in patients aged in their 20s and is characterised by progressive gastrointestinal dysmotility, neuropathy and leukoencephalopathy [66]. There is currently no disease-specific therapy. Erythrocyte-encapsulated thymidine phosphorylase (EE-TP) is an emerging clinical therapy. EE TP is intravenously infused into a patient and aims to replace defective thymidine phosphorylase activity [66]. A phase 2, multicentre, multiple-dose, open-label trial is currently being conducted to assess the medication’s safety, tolerability, pharmacodynamics and efficacy [66].

Dietary Supplements as Emerging Treatment in Mitochondrial Disease

A mainstay in the treatment of many inborn errors of metabolism is dietary manipulation. This may include dietary restriction strategies or supplementation that aim to limit toxic effects, maximise residual enzyme function or utilise alternative metabolic pathways [67, 68]. While dietary restriction has not found favour in managing mitochondrial disease, dietary supplements have been purported to be effective through a range of cellular mechanisms [67]. There are numerous theoretical reasons why certain supplements may improve metabolic functions. For example, creatine could potentially be used as an alternative energy source boosting mitochondrial ATP production [69]. Other supplements including antioxidants (vitamin C, vitamin E and alpha-lipoic acid) and electron acceptors (CoQ10 or carthine) may remove ROS from cells, improving mitochondrial function. Supplements could also bypass a cellular defect (e.g. a deficiency in the activity of complexes I, II or III in the electron transport chain) [69-71]. The potential benefits of dietary supplementation are demonstrated by an open-label trial (NCT03973203) in five patients with adult-onset mitochondrial myopathy. In this trial, dietary supplement with niacin (i.e. an NAD+ booster) increased muscle strength and mitochondrial biogenesis of affected patients when compared to healthy matched controls [72]. Despite their theoretical potential, there is a paucity of robust evidence to support the routine use of dietary supplements in all types of mitochondrial diseases.

Although there may be a potential clinical benefit of dietary supplementation use, there is a lack of high-quality evidence demonstrating their efficacy [10, 12]. The majority of favourable evidence available is from low-quality studies that lack robust designs to effectively demonstrate that the intervention studied was responsible for the reported benefit (e.g. case reports, retrospective studies and small underpowered non-RCTs) (Table 3) [73-106]. Another issue that has been encountered in dietary interventional trials is the heterogeneity in the composition, combination, dosing regimens and duration of treatment [12]. Generating high-quality evidence for the use of dietary supplements through RCTs is challenging. Studies are often underpowered with highly variable designs that lack standardization. This makes comparing study results difficult and prevents meta-analysis [70]. Recruitment to clinical trials is also difficult as supplements are commonly used by patients, excluding their inclusion into the study [70]. Additionally, some patients are reluctant to join a study that might assign them to a placebo group where they will be required to temporarily stop their usual supplement use [70]. Further work is required to build a more rigorous evidence base through larger multicentre RCTs.

Table 3

Summary of the current and emerging dietary supplements’ therapeutic landscape

Supplement	Mechanism	Disease(s)/syndrome(s) investigated	Study design/trial phase	N	Most recent update/publication	Results	Trial ID/reference
Monotherapy (74-94)
Alpha-lipoic acid	Antioxidant cofactor for mitochondrial alpha-keto acid dehydrogenases	CPEO	Case report	1	1995	Improved brain and skeletal muscle energy metabolism	[73]
L-arginine	Precursor of nitric oxide that stimulates vasodilation	MELAS	Case series	3	2002	Improved microcirculation and reduced tissue injury from ischemia	[74]
			Open-label clinical trial	24	2005	Reduced frequency and severity of stroke-like symptoms	[75]
			Open-label clinical trial	15	2006	Improved endothelial function	[76]
			Open-label clinical trial	25	2007	Reduced stroke like-symptoms	[77]
Carnitine -	Removal of toxic acetyl coenzyme A metabolites -	PMM CPEO	Crossover	10	2015	Improved aerobic performance	[78]
		CPEO KSS MELAS ME PMM Leigh	Open-label clinical trial	21	1993	Normalization of plasma carnitine levels Improved muscle tone and strength Improved cardiomyopathy	[79]
L-citrulline	Stimulates vasodilation	MELAS	Phase 1	24	2020	Pending	NCT03952234
		MELAS	Small kinetic study	20	2012	Increased NO production	[80]
		MELAS	Small kinetic study	10	2016	Increased NO production	[81]
CoQ10	Antioxidant that transfers electrons from complex I to II and III	Familial cerebellar ataxia with muscle CoQ10 deficiency	Case Series	6	2011	Increased strength Reduced ataxia Reduced seizure frequency	[82]
		MERRF MELAS CPEO	Crossover	8	1997	Increased muscle strength	[83]
		PMDs	Two phase prospective study	44	1990	Increased activity of mitochondrial respiratory chain enzymes Increased muscle strength	[84]
		Ophthalmoplegia plus syndrome CPEO KSS	Open-label	9	1998	Reduced lactate after exercise	[85]
		CPEO ME	Open-label	8	1996	No improvement in exercise performance	[86]
Creatine	Regenerates ATP	MELAS PMM	Crossover	7	1997	Increase in ischemic isometric hand grip strength isometric, dorsiflexion torque	[87]
		KSS MELAS NARP	Open-label	5	2003	Increase in maximal muscle performance	[88]
		CPEO PMM	Phase 2	16	2000	No significant clinical findings	[89]
		CPEO KSS	Phase 2	15	2005	No significant clinical findings	[90]
Folinic acid	Increases brain 5-MTHF levels; believed to reduce white matter demyelination	KSS with cerebral 5-MTHF deficiency	Open-label study	8	2014	Improvements in ataxia and tremor	[91]
		Cerebral folate deficiency and leukoencephalopathy	Case report	1	2006	Improved white matter myelinization	[92]
Niacin	Increased NAD+ and NADH; increase complex I function	MELAS	Case report	1	1996	No significant clinical findings	[93]
		PMM	Phase 2	15	2019	Improves muscle strength	NCT03973203
Mito Q	Mitochondrial targeted antioxidant	Mitochondrial oxidative stress in chronic kidney disease	Phase 3	24	2019	Currently recruiting	NCT02364648
Nicotinamide	NAD+ precursor	PMD	Open-label	15	2019	Currently recruiting	NCT03432871
Riboflavin	Component of electron carriers flavin adenine dinucleotide and flavin mononucleotide.	PMM	Case series	5	1993	Complex I activity appeared normalised but no clinical improvement	[94]
		Myopathic complex I deficiency	Case report	1	1997	Improved muscular metabolic function and strength	[95]
		ME	Case report	1	2013	Improved muscle strength	[96]
Resveratrol	Fatty acid involved in fatty acid oxidation	PMM Fatty acid oxidation defects	Phase 2	20	2019	Completed; awaiting results	NCT03728777
Thiamine	Coenzyme in oxidative decarboxylation	PMD	Case series	2	1981	Reduced perceived fatigue	[97]
Combination therapy
L-arginine and L-citrulline	-	Multi-organ PMD	Crossover	20	2020	Completed; awaiting results	NCT02809170
		MELAS	Phase 1	30	2016	Completed; awaiting results	NCT01339494
ALA, CoQ10, and creatine	-	Multi-organ PMD	Crossover study	18	2007	Improvement in plasma lactate and oxidative stress after exercise	[98]
Carnitine and riboflavin	-	PMM	Case report	1	1991	Increased muscle strength	[99]
Carnitine, CoQ10, vitamin C, vitamin K1 and vitamin B complex	-	LHON CPEO MELAS NARP COXD	Open-label	12	2004	No significant clinical findings	[100]
Carnitine, CoQ10, vitamin C, vitamin E, vitamin K3 and riboflavin	-	CPEO CPEO KSS	Open-label	13	1998	Improvement in mild disease symptoms	[101]
CoQ10, vitamin C, vitamin E and vitamin K3		PMM KSS MELAS MERRF	Open-label	16	1995	No significant clinical findings	[102]
CoQ10, vitamin C, vitamin K3, niacin, riboflavin and thiamin		KSS MERRF PMM PMM with demyelinating neuropathy	Open-label	16	1993	No significant clinical findings	[103]
Folinic acid and riboflavin		ME and cerebral 5-methyltetrahydrofolate deficiency	Case report	1	2007	Reduced white matter demyelination	[104]
Vitamin C and vitamin K3		Complex III deficiency	Case report	1	1986	Improved exercise tolerance	[105]
		Complex III deficiency	Case report	1	1995	No significant clinical findings	[106]

ALA α-Linolenic acid, ATP adenosine triphosphate, COCXD cytochrome C oxidase deficiency, CPEO chronic progressive external ophthalmoplegia, CoQ coenzyme Q10, KSS Kearns-Sayre syndrome, LHON Leber's hereditary optic neuropathy, MIDD maternally inherited diabetes-deafness syndrome, MELAS mitochondrial encephalopathy lactic acidosis and stroke-like episodes, MERR myoclonic epilepsy with ragged red fibres, ME mitochondrial encephalopathy, NARP neuropathy ataxia and retinitis pigmentosa, PMD primary mitochondrial disease, PMM primary mitochondrial myopathies

-

-

The lack of high quality evidence means that there are no regulatory approved dietary supplements to treat, mitigate or cure PMD in either the EU or the USA [107]. Despite these legalities, dietary supplements are frequently used for this purpose either as monotherapy or as polytherapy (known as a mitochondrial cocktail) due to the theoretical synergistic benefit [67]. However, there is no known standardisation nationally or internationally, with their clinical use often dependent on centre or physician preference as opposed to evidence-based guidelines [108].

Diet as an Emerging Therapy

The neurological manifestations of mitochondrial disease can make both food consumption and ingestion more difficult [73]. In addition to this, the diet of patients with mitochondrial disease tends to be deficient in protein, calcium and fluid [109, 110]. These dietary deficiencies mean that patients are at higher risk of malnutrition than the general population [109, 110]. Therefore, individualised dietary counselling and monitoring is a simple approach to address these effectively. The role of dietary adaptation in PMD can also include several other strategies depending on the clinical features and genetic predisposition. Among them, the three most investigated diets are the ketogenic diet (KD), low-residue diet (LRD) and high-nitrate diet [111-113]. However, despite the potential offered by these diets in improving symptoms of mitochondrial function in PMD, there have been few disease-specific clinical trials. This is likely due to challenges in patient recruitment and retention, given the restrictive nature of dietary interventional trials.

The KD involves replacing the majority of a patient’s dietary consumption of carbohydrates with fat (defined as < 20 g of carbohydrate per day) [114]. This reduction in carbohydrate places the body into a metabolic state of ketosis [114]. The KD may have multiple benefits in PMD. The first benefit is that the KD may better control intractable epilepsy regardless of the underlying neurological or metabolic cause [114]. The specific mechanism of how the KD reduces epileptic activity is unclear [114]. There have been numerous RCTs demonstrating that the KD has efficacy in treating non-disease-specific intractable epilepsy [115]. However, a 2020 Cochrane review concluded that the current evidence base is inconclusive [115]. The review cited not only a lack of studies but criticised the majority of the RTCs for both a lack of power but also a short follow-up [115]. However, numerous observational studies have demonstrated a benefit of the KD in reducing intractable epilepsy in PMD [111, 116, 117]. Furthermore, a Swedish cohort study in paediatric patients with PDCD (n = 19) demonstrated that a KD not only reduced epileptic seizures, but also improved ataxia, sleep disturbance, speech/language development, social functioning and frequency of hospitalizations [118]. Additionally, the state of ketosis may be beneficial to mitochondrial function; there is preclinical evidence from in vivo (using cultured human cell lines) and in vitro (murine models) that the state of ketosis improves mitochondrial function (Table 4) [119-122]. However, no study in man has been conducted to asses if this could translate into clinical practice. To establish if the KD is an effective treatment for PMD-specific (and non-specific) intractable epilepsy and improving in vivo mitochondrial function, a large RCT is required. This trial should not only assess an epileptic control cohort, but also include objective assessments of mitochondrial and global neurological function. This could potentially be a sub-arm of a larger definitive trial to establish the efficacy of the KD in treating intractable epilepsy.

Table 4

Summary of how the ketogenic diet may benefit mitochondrial function

Mechanism	Model	Condition modelled	Reference
Reduces deleted mDNA	Cultured human cells	KSS	[119]
Induced mitochondrial biogenesis	Deletor mouse	PEO	[120]
Restored complex I assembly, increasing ATP synthesis	Embryonic stem cells	MELAS	[121]
Subacute selective ragged‐red‐fibre lysis	Cultured human cells	PMM	[122]

ATP adenosine triphosphate, KSS Kearns-Sayre syndrome, mDNA mitochondrial deoxyribonucleic acid, MELAS mitochondrial encephalopathy, lactic acidosis, and stroke-like episodes, PEO progressive external ophthalmoplegia, PMM primary mitochondrial myopathies

The second diet investigated in MD is a low residue diet (LRD; a diet with less than 10 g fibre per day) [123]. Mitochondrial dysfunction in the smooth muscle of the gastrointestinal tract causes various symptoms including abdominal pain, bloating and severe constipation, frequently leading to hospital admission [112]. Therefore, in contrast to mainstream dietary advice, the LRD requires patients to reduce their intake of dietary fibre. The diet was initially designed for people with inflammatory bowel disease to prevent the obstruction of inflamed bowel because fibre provides resistance to the defective peristaltic action of diseased smooth muscle [112]. A phase 2 feasibility study of the efficacy and acceptability of a LRD in adult patients with PMD has been completed with the results due to be published imminently (NCT03388528).

There is also evidence that a high-nitrate diet can benefit the function of mitochondria [113]. Nitrate is an inorganic anion that is found in high quantities in root vegetables [113]. Once ingested, it is converted into bioactive nitrogen oxides, which reduces the concentration of ATP/ADP translocase improving basal mitochondrial function [113]. A double-blind crossover trial in healthy participants demonstrated that a high-nitrate diet improved oxidative phosphorylation and reduced oxygen demand during exercise in harvested muscle [113]. To date, there have been no studies extending this finding to patients with PMD, leaving this a ripe area of research in PMD despite the likely challenges of patient recruitment and retention. Dietary supplementation with nitrate supplements could be an alternative therapeutic avenue.

Device Use as Emerging Treatment

Bioengineering has resulted in the development of multiple devices to treat various neurological diseases with many now approved by the FDA [124]. There are two promising devices under development to treat PMD: near-infrared light-emitting diode (NIR-LED) and transcranial direct current stimulation (TDCS) (Table 5) [125-127]. These devices have the potential to open another valuable therapeutic front in both treating the symptoms of PMD and also altering the underlying pathophysiology. Like many therapies for PMD, there is currently a lack of evidence to assess their efficacy, meaning that rigorous clinical trials are needed to realise this potential.

Table 5

Summary of the emerging device use for mitochondrial disease

Device	Mechanism	Condition treated	Study design	N	Most recent update/publication	Status/results	Trial ID/reference
Near-infrared light-emitting diode	Increases expression of cytochrome c oxidase, reducing mitochondrial toxicity	LHON	Open-label clinical trial	4	2014	Terminated	NCT01389817
Transcranial direct current stimulation (tDCS) -	Neuromodulation	POLG‐related mitochondrial epilepsy -	Case report	1	2018	Efficacious in treating refractory focal motor seizures	[126]
			Case report	1	2019	No statistically or clinically significant reduction of seizures	[127]

LHON Leber's hereditary optic neuropathy, POLG DNA polymerase gamma, catalytic subunit

-

-

NIR-LED uses low-energy lasers or light-emitting diodes to radiate tissue with light at near infrared range (630–1,000 nm) of the electromagnetic spectrum [125]. There is in vivo and in vitro preclinical evidence that the technology improves mitochondrial function [125]. The NIR light radiates the mitochondrial photoacceptor molecule cytochrome C oxidase, thereby activating it. Once activated, cytochrome C oxidase increases the expression of mitochondrial proteins involved in antioxidant protection and energy production [125]. To date, there has only been one open-label phase 1/2 clinical trial assessing the therapeutic benefit of using NIR-LED to treat LHON (n = 4 patients) (NCT01389817). The study intended to assess the N95 retinal ganglion cell peak as its primary outcome. However, it was terminated due to difficulties obtaining this measurement in LHON patients. Further studies are therefore required that utilise more refined measurable outcomes.

TDCS is a neuromodulatory technique that involves delivery of a constant direct current to the cortex of the brain via electrodes placed on the skin of the head [128]. This current alters the resting membrane potential of cortical neurons, resulting in neuronal depolarisation or hyperpolarisation [128, 129]. The resulting decrease in firing neurons has been shown to have therapeutic potential in patients with resistant epilepsy and status epilepticus with emerging preclinical and clinical evidence [128, 129]. In a double-blind, sham-controlled RCT, TDCS reduced seizure frequency in patients with refractory focal epilepsy (n = 70) [129]. Two case reports have also utilised this technology for treatment of POLG‐related mitochondrial epilepsy [126, 127], with conflicting findings: one study reported efficacy in control status epilepticus while the other observed no benefit [126, 127].

Exercise as a Treatment

Progressive proximal skeletal myopathy is a prominent clinical feature of many different PMDs. Impaired mitochondrial oxidative phosphorylation due to respiratory chain defects frequently result in symptoms of exercise intolerance, muscle weakness and muscle fatigue even with minimal exertion [130]. As well as a reduced aerobic capacity, patients with PMD are less physically active compared to matched controls, consequently exacerbating muscle deconditioning and function [131].

Exercise training involves frequently repeated bouts of skeletal muscle contraction. Aerobic exercise training is widely accepted as a potent stimulator of mitochondrial biogenesis, therefore representing a potential therapeutic intervention for mitochondrial disease [87, 88]. Indeed, it is firmly established that aerobic exercise training in patients with PMD results in a number of metabolic and physiological adaptations including an increase in oxygen consumption and work capacity, mediated by an increase in oxygen extraction [132-141]. Importantly, these improvements have been shown to translate into clinically meaningful increases in quality of life and self-reported activities of daily living [134, 136, 141]. Other significant benefits include enhanced magnetic resonance spectroscopy (MRS) recovery kinetics and a decrease in blood lactate at rest and with exercise, suggesting reduced anaerobic metabolism [132, 136, 142].

At a molecular genetic level, one of the first exercise interventional studies in patients with PMD raised concerns of a potential selective amplification of mitochondrial pathogenic variant deletion [143]. However, an increase in mDNA heteroplasmy has not been replicated by this group or others [134, 137]. Further, skeletal muscle biopsy studies in patients with mitochondrial disease have demonstrated an aerobic exercise training-induced improvement in skeletal muscle oxidative capacity and mitochondrial biogenesis reflected by an increase in respiratory chain complex activities and mitochondrial volume [132, 134, 141, 144].

Resistance exercise training has also been investigated as a potential intervention for patients with mitochondrial myopathy caused by sporadic mtDNA point pathogenic variants or single large-scale mDNA deletions. It was postulated that the myofiber damage-induced activation of muscle stem cells (satellite cells; predominantly containing wild-type mtDNA) may consequently reduce mtDNA mutant load (i.e. the mitochondrial DNA shifting theory) [145-147]. Strength training has been shown to effectively increase muscle strength1,2 despite no significant effect on mutated mtDNA, muscle fibre area or mtDNA copy number2. Importantly, strength training benefits translate to an enhanced aerobic capacity (p = 0.06), mediated largely by an increased peak oxygen extraction (a-vO2 difference) [148].

The abundance of evidence suggests that exercise training is efficacious, well tolerated and safe; no studies report clinical adverse events or detrimental effects on muscle (serum creatine kinase levels), perceived fatigue or self-reported activities of daily living [132, 134, 136, 137, 141, 143, 147, 148]. Our recently conducted systematic review and meta-analysis to determine the effect of exercise across a range of outcomes in patients with neuromuscular disorders, which includes mitochondrial disease, also supports these findings [149]. While further research is required to fully elucidate the mechanisms of the potential therapeutic benefit of exercise training, these results encourage the translation of exercise treatment into the clinical care of patients with mitochondrial disease [150]. A combination of progressively prescribed aerobic and strength exercise training is recommended; however, it should be noted that this is limited to those who are physically capable, highlighting the necessity for the development of pharmaceutical drugs that mimic the effect of exercise [12]. A summary of the literature is presented in Table 6 [151].

Table 6

Summary of exercise training studies in mitochondrial disease.

Exercise training intervention	Disease(s)/syndrome(s) investigated	Study design	N, gender and age; mean ± SD (range)	Most recent publication	Results	References
3d·wk−1 for 16 wks; cycle ergometer; 70–80% VO2max; 30 min	m.3243A>G pathogenic variant (n = 10) Exercise intolerance (n = 10)	SGT+ HCs	10 6M/4F; 39 ± 11·8	2015	Increased VO2peak (mL/min, mL/kg/min, % predicted) Peak power Peak a-vO2 difference (mL/dL) VO2 at VAT (mL/min/kg) Left ventricular mass and left ventricular mass index	[135] [140]
~4d·wk-1 for 12 wks; stationary bike; 65–75% VO2max; 30 min	m.3243A>G pathogenic variant (n = 13), single large-scale deletions (n = 5), 8344 A>G pathogenic variant (n = 1), ND2 microdeletion (n = 1) Exercise intolerance (n = 14)	SGT + HCs	20 10M/10F; 41 ± 12 (26–57)	2006	Increased VO2peak (mL/kg/min) Peak power Citrate synthase activity Ratio between mDNA and nDNA Self-reported walking distance Self-reported muscle strength Self-reported endurance Self-reported physical activity Decreased Capillary density Fatigue	[134]
5d·wk-1 for 12 wks; stationary bike; 70% VO2max; 30 min 3–12 months of deconditioning prior to long-term study: 3d·wk-1 for 12 months (n = 3); 6 months (n = 1)	m.3243A>G pathogenic variant (n = 1), single large-scale deletions (n = 1), 8344 A>G pathogenic variant (n = 1), ND2 microdeletion (n = 1) Exercise intolerance (n = 4). Patients in prior study 3	SGT	4 4M; 31·8 ± 4 (27–36)	2009	Increased VO2peak (mL/kg/min) Peak power Citrate synthase activity (12 wks only) Type I fibre area (6 months only) Capillary density (12 months only) Self-reported muscle strength Self-reported endurance	[141]
4d·wk-1 for 12 wks; cycle ergometer; 65–70% HRmax; 30 min for 1st 6 wks, 45 min thereafter (split into 15 or 30 min)	Metabolic myopathy (n = 6). Varied from no functional impairment to significant exercise intolerance.	SGT	6 4M/2F; 51 ± 16	2016	Increased VO2peak (L/min, mL/kg/min) and ↑ VCO2 peak (L/min) Peak power Peak stroke volume Cardiac output Muscle oxygenation index obtained by near-infrared spectroscopy (NIRS) Constant work rate exercise test (50% pre-training maximal workload): Decreased Peak rate of perceived exertion (RPE) Constant work rate exercise test (50% pre-training maximal workload): Decreased VO2 (L/min, mL/kg/min) VE HR Cardiac output RPE O2 cost of cycling (mL·min-1·watt-1)	[139]
~3–4d·wk-1 for 10 wks; cycle ergometer; Constant near-lactate threshold workload: ≤ 70 HRmax; 30 min for 1st 5 wks, 45 min (with 5-min rest halfway), thereafter	Single large-scale deletions (n = 6), multiple deletions (n = 3), A5814G mtDNA point pathogenic variant (n = 1), pathogenic variant unknown (n = 2) Mitochondrial myopathy (n = 12)	SGT + HCs	12 1M/11F; 46·7 ± 5·6 SE	1999	Increased QoL (SF-36) Decreased Peak blood lactate during constant near-lactate threshold workload test	[142]
	Single large-scale deletions (n = 4), multiple deletions (n = 3) Mitochondrial myopathy (n = 7)	SGT	7 1M/6F; 44·9 ± 12·1 (28–62)	2012 24	Decreased Resting plasma lipoperoxide	[150]
3–4d·wk-1 for 8 wks; treadmill walking; 60–80% HRR; 20- to 30-min (bouts if required for ~1st 4 wks with rest: time taken for HR to ↓ within 10% pre-HR)	mtDNA deletion (n = 5), 8344 A>G pathogenic variant (n = 1), tRNA(Leu (CUN)) pathogenic variant (n = 1), Unknown pathogenic variants (n = 3) Exercise intolerance (n = 10), muscle weakness (n = 10), mitochondrial myopathy (n = 6), lactic acidosis (n = 8)	SGT	10 4M/6F; 36 ± 9 (25–58)	1998	Increased Exercise duration QoL (SF-36: Physical component summary) Decreased Resting HR Resting blood lactate ADP recovery half-time Submaximal exercise test (80% predicted HRmax): Increased Aerobic capacity (METS) Decreased Blood lactate at 70% pre-training predicted HRmax HR	[136]
3–4d·wk-1 for 8 wks; treadmill walking; 70–85% HRR; 20- to 30-min	10 patients in prior study 4. Additional 4 patients: mtDNA deletion. Mitochondrial myopathy (n = 3)	SGT + HCs	14 4M/10F; 36·4 ± 9·8 (14–58)	1999	Increased QoL (SF-36) Decreased Resting blood lactate ADP recovery half time Submaximal exercise test (85% predicted HRR): Increased Aerobic capacity (METS) Decreased Blood lactate at 70% pre-training predicted HR	[143]
3–4d·wk-1 for 14 weeks; cycle ergometer; 70–80% HRmax; 30- to 40-min (30 min for the 1st 7 weeks, 40 min thereafter)	Unidentified (n = 1), TRNAGlu (n = 1), TrpT5543C pathogenic variant (n = 1)*, ND4 pathogenic variant (n = 1)*, G5920A pathogenic variant (n = 1)*, G14846A pathogenic variant (n = 1)*, cytochrome b deletion (n = 1)*, single, large-scale deletions (n = 2)*, 15-bp Microdeletion COX subunit III (n = 1)* Exercise intolerance (n = 10)	SGT	10 4M/6F; 39·3 ± 9·5 (24–53) n = 8*	2007	Increased VO2peak (mL/kg/min) Peak power Peak a-vO2 difference (mL/dL) Initial rate of PCr resynthesis (V) Apparent maximum rate of oxidative ATP synthesis (Qmax) Citrate synthase activity Complex II activity Complex IV activity Mutant mtDNA relative to total mtDNA (%) Cytochrome c protein mtHSP70 protein MnSOD protein Bax protein Decreased Resting HR HR at 70–80% pre-training maximal workload Peak blood lactate Whole muscle aconitase activity/mU mitochondria (Complex IV) OGG-1 protein	[132]
3–4d·wk-1 for 14 wks* (3·wk-1 for the 1st 7 wks, 4d·wk-1 thereafter); cycle ergometer; 70–80% HRmax; 30 min for the 1st 7 wks, 40 min thereafter *Randomised to continue until 28 wks (n = 4) or cease (n = 4)	Single large-scale deletions (n = 8). Exercise intolerance to a varying degree (mild to severe) (n = 8)	SGT	8 3M/5F; 40·8 ± 9·7 (25–60)	2006	Increased VO2peak (L/min) Peak power Peak a-vO2 difference (mL/dL) QoL (SF-36: Physical component summary) Submaximal constant work rate exercise test (60% HRmax) Decreased RPE HR Blood lactate	[137]
3d·wk-1 for 12 wks; cycle ergometer; 70–80% HRmax; 30 min	m.3243A>G pathogenic variant (n = 5), Ragged-red fibers (n = 5) Muscle weakness or mitochondrial myopathy (n = 10)	SGT	10 3M/7F; 42 ± 14 (20–64)	2006	Increased O2 extraction (↓ O2 uptake efficiency slope, i.e. index of cardiorespiratory functional reserve) Peak power Initial rate of PCr resynthesis (V) Apparent maximum rate of oxidative ATP synthesis (Qmax) 6MWT distance Quadriceps whole muscle volume (dm3) Quadriceps whole muscle cross-sectional area	[141]
3d·wk-1 for 12 wks. Bilateral leg extensors and leg press (3 x 6–8 reps, 80–85% 1-RM, full recovery between sets)	Single large-scale deletions (n = 8) Exercise intolerance to a varying degree (mild to severe) (n = 8)	SGT	8 8F; 38·6 ± 7 (25–48)	2008	Increased 1-RM knee extension 1-RM leg press Peak a-vO2 difference (mL/dL) nMHC fibres (%) Centrally nucleated fibres (%) NCAM positive fibres (%) Decreased COX-deficient fibres (%)	[137]
3d·wk-1 for 12 wks. Aerobic training: cycle ergometer; 70% peak work rate; 30 min Strength training: dynamic isotonic shoulder press, butterfly, biceps curls; 1 × 10–15 reps in 1st 2 wks, 2–3 sets thereafter); 50% 1-RM; ~20 min	Exercise intolerance (n = 7), muscle weakness or mitochondrial myopathy (n = 2)	RCT (parallel)	9 5M/4F; 44·8 ± 8 (35–57)	2005	Increased 1-RM butterfly (pectoralis major) 1-RM shoulder press VO2peak (L/min, % predicted) VAT (% predicted) Peak O2 pulse (% predicted) HRmax (% predicted) RER/power slope Peak VE Peak breathing frequency Maximum expiratory pressure Maximum inspiratory pressure Submaximal constant work rate exercise test (70% pre-training maximal workload): Increased Time and distance until exhaustion	[138]

Results reported refer to statistically significant changes (P < 0.05) compared to before training

6MWT 6-min walk test, HCs healthy controls (exercise-trained), a-vO difference arterial–venous O2 difference, HR heart rate, HRR heart rate reserve, mtHSP70 mitochondrial 70-kDa heat shock, MnSOD manganese superoxide dismutase, NCAM neural cell adhesion molecule, nMHC neonatal myosin heavy chain, OGG-1 8-oxoguanine DNA glycolase-1, QoL quality of life, RER respiratory exchange ratio, SF-36 36-Item Short Form Survey SGT single-group trial, VAT ventilatory anaerobic threshold, VE pulmonary ventilation

Mitochondrial Replacement Therapy

The severity and intensity of PMD means that preventing genetic transmission is highly desirable. Current preventative therapies include voluntary childlessness, adoption, oocyte donation, prenatal testing and preimplantation genetic diagnosis (PGD) [152]. There are numerous considerations for each technique. Voluntary childlessness, adoption and oocyte donation may be personally or culturally unacceptable [152]. Prenatal testing is only suitable for women who have a low risk of transmission of mtDNA disease and who would be willing to terminate an affected fetus [153]. There is also a procedural risk to the viability of the pregnancy with a miscarriage rate of 1–2% following chorionic villus biopsy [153]. PGD involves testing in vitro-generated embryos for a pathogenic variant before subsequent implantation. This means the technique is limited by the number of embryos available with pathogenic variant levels that are unlikely to result in severe PMD [152]. Additionally, PGD is a modified version of in vitro fertilization and therefore has associated risks, namely increased risk of multiple and ectopic pregnancies [153]. In contrast to Mendelian genetic disorders, PGD and prenatal testing face unique limitations in PMD. Hetroplasmy (variable levels of mutated mtDNA) and a highly heterogeneous disease phenotype make it impossible to predict PMD severity in any subsequent children. This highlights the need to prevent transmission of mtDNA but allow the transmission of nDNA.

Over the last decade, and following a change in UK law, it has become possible to offer mitochondrial replacement therapy (MRT), otherwise known as mitochondrial donation, as a means of preventing transmission of mtDNA disease [152, 154]. In the UK, mitochondrial donation can be offered to women with homoplasmic or high-level heteroplasmic mtDNA variants when there is an expectation of transmitting severe disease and preimplantation genetic diagnosis is not considered suitable [119, 120]. Two slightly different forms of MRT can be employed, pronuclear transfer (PNT) or maternal spindle transfer (MST). PNT involves the in vitro fertilization of oocytes from both the intending mother and donor with sperm from the intending father [152, 154]. The pronuclei are then removed from the donor oocyte and replaced with the pronuclei from the intending mother’s fertilised oocyte [152, 154]. In the alternative approach, MST, the metaphase II spindles from the donor oocyte are removed and replaced with those from the intending mother’s oocyte. The resulting oocyte is then fertilised in vitro with the intending father’s sperm [152, 154]. In both techniques the resulting foetus has the nuclear DNA of both parents but the mitochondrial DNA of the donor [152, 154]. MRT has produced viable embryos and subsequent offspring in murine, primates and man [155-157]. However, mice conceived through MST MRT have been shown to have defective biochemical processes (increased production of ROS, defective proteostasis and insulin resistance), resulting in mice that aged prematurely [158]. These studies used inbred conplastic murine strains, a contrasting situation to the high genetic diversity observed in the human population. There are some other possible technical limitations, with some 20% of stem cell lines derived from embryos after PNT reverting to the maternal mtDNA genotype. The cause for this reversion remains unknown, but it only appears to occur following prolonged culture in an unrestricted environment [158].

Despite the legal and ethical challenges posed by MRT, in 2015 the UK became the first country in the world to create the legislative framework required to allow clinical trials to assess the long-term efficacy and safety of the technology in humans [159]. Multiple children have now been born through MRT globally in unregulated environments with no current reported developmental concerns [160]. A clinical trial of the first 75 children born via MRT is currently being conducted at the Wellcome Centre for Mitochondrial Research at the Newcastle University. The study aims to identify if there are any long-term developmental concerns from the technique in humans.

Other Therapeutic Options

There are various other exciting clinical therapies currently being developed including cell replacement, gene therapy, mitochondrial augmentation therapy (MAT), hypoxic therapy and mtDNA base editing [129, 161, 162, 162, 163].

Gene therapy is an emerging experimental technique using vectors (e.g. viruses) to replace pathogenic genes with the respective functional wild types [164]. As PMD is caused by both pathogenic variants in mtDNA and nDNA, there are two targets for genes therapy [164]. Various in vivo and in vitro preclinical studies have successfully replaced mutated nDNA and mtDNA using adeno-associated viruses (AAVs) and CRISPR/Cas9 in a variety of PMDs [130, 131, 133, 134]. Although much of the literature is preclinical, the technology has now moved into early-stage clinical trials in LHON. A phase 1 clinical trial of nine patients demonstrated that recombinant AAV vector ND4 (rAAV2) gene therapy was safe and tolerated in a long-term follow-up [165]. A further phase 1 study is currently investigating the safety and efficacy of an AAV vector gene therapy of LHON in 30 patients (NCT02064569), whilst a phase 1/2 study is currently investigating the safety and efficacy of scAAV2-P1ND4v2 in 30 patients (NCT02161380).

Cell-replacement therapy involves restoring the loss of function of a diseased tissue by replacing the defective cells with effective cells [166]. In PMD, a patient’s cells are replaced with cells from another individual with unaffected nDNA or mtDNA leading to the production of functioning mitochondrial proteins [22, 167]. Cell-replacement therapy is only likely to be effective in treating PMD when the disease presents as a consequence of defective mitochondria in a specific replaceable tissue (e.g. the liver or bone marrow), and not disorders that affect tissues systemically. Hematopoietic stem cell transplantation has been shown to increases long-term survival in patients with mitochondrial neurogastrointestinal encephalomyopathy [22]. Cell-replacement therapy via liver transplantation has been shown to improve multiple symptoms in ethylmalonic encephalopathy due to pathogenic variants in ETHE1 [167]. As cell-replacement therapy is likely to be a disease-specific therapy in PMD, further research is required to conduct intervention specific trials in specific diseases.

MAT is another emerging treatment for PMD that has recently entered early-stage clinical trials. In MAT, human mitochondria are extracted from white blood cells derived from a patient’s mothers’ serum [163]. A patient is then subsequently treated with filgrastim to stimulate the release of CD34+ hematopoietic stem cells. These stem cells can then be removed by apheresis and co-cultured in vitro with the donor’s extracted mitochondria [163]. The stem cells can then be returned to the affected individual by infusion [163]. The FDA recently granted fast-track, orphan drug and rare paediatric disease designations to the treatment. This facilitated the development of an open-label combined phase 1 and 2 clinical trial (NCT03384420) (n = 7) investigating the efficacy of the treatment in Pearson’s syndrome (a rare and severe neonatal mitochondrial deletion syndrome) due to report in 2021.

There is emerging preclinical in vivo and in vitro experimental evidence that stimulating a hypoxic response may benefit mitochondrial function in mitochondrial disease [168]. Models of PMD were created by treating human cells lines and zebrafish models with respiratory chain (RC) inhibitors [168]. When these models were treated with a hypoxia-inducible factor they demonstrated increased growth when compared to non-treated controls [168]. Additionally, in vivo murine models of Leigh syndrome (Ndufs4 KO) demonstrated improved survival and locomotor activity after continuously breathing 11% oxygen [168]. Although these experiments are promising they need to be validated in more complex clinically relevant models of human PMD [168]. Despite the potential benefit offered by hypoxic therapy, it is likely to be highly challenging to organically create a hypoxic response in humans. Given that patients with Leigh syndrome may already have an impaired respiratory drive due to brainstem lesions, it would be highly impractical and potentially dangerous for patients to continuously breath air with a depleted oxygen content (supplied by a breathing device). However, the hypoxic response may be better exploited as a pharmacological target.

Manipulating the mitochondrial genome to remove pathogenic variants is of interest to clinicians and researchers, but a feasible method is still elusive [1]. Several targeted gene-editing techniques such as anti-sense peptide nucleic acids (endonucleases, TALENS (transcription activator-like effector nucleases), zinc-finger nucleases and Crispr-Cas9) have recently emerged in the laboratory to do this, but none of them are anywhere near human trials [1]. Even in the laboratory settings, there are challenges to overcome, namely the impermeability of the inner mitochondrial membrane and the lack of selective molecules to cause timely degradation of mutant mtDNA [1]. Thus, the manipulation of mtDNA to date has been limited to the targeted destruction of the mitochondrial genome by designer nucleases [169]. The use of RNA-free DddA-derived cytosine base editors promise the potential to enable CRISPR-free mitochondrial base editing [169]. Although this technology offers the exciting prospect of being able to remove mutations from the mitochondrial genome, this preclinical approach is yet to be used even in basic animal models.

Conclusion

The rarity of PMD along with its clinical and scientific complexity makes developing treatment an enormous challenge, with only one disease-specific pharmacological agent in current clinical practice. However, there have been major recent advances in the fundamental understanding of PMD through the establishment of national cohorts and the widespread use of gene agnostic next-generation sequencing approaches. This has resulted in a truly exciting emerging therapeutic arsenal. To develop effective treatment and establish a more concrete evidence base for existing clinical guidelines, extensive high-powered comprehensive clinical trials must now be conducted. Given the heterogeneity and rarity of PMD, these trials will need multicentre collaboration and detailed phenotype-specific subgroup analysis. This is a major challenge given that some of the most beneficial therapies (i.e. exercise, diet, supplements and off-patent repurposed medications) have limited commercial incentive. This highlights the role that charities and governments must play in funding the development of an evidence-base that will enable translation of treatment from the bench to bedside in PMD. Historically, clinical trials have typically used biomarkers as primary outcomes that are not relevant to clinicians or to patients’ lives. Many of these biomarkers have been used due to their ability to allow statistical analysis and not because they can capture the benefit of a treatment on a patient’s quality of life. This highlights the importance of co-designing clinical trials, based on what matters to patients. Any future trials of value should utilise established international cohorts of patients with PMD and employ internationally agreed outcome measures that are clinically meaningful and patient relevant. This will not only aid the recruitment of patients but provide an international infrastructure to assess the efficacy of treatment.

Below is the link to the electronic supplementary material.

Supplementary file1 (DOCX 187 KB)

Novel pharmacological agents are under development to treat mitochondrial disease.

There is an emerging field of non-pharmacological treatments that have not been comprehensively reviewed in the literature.

Rigorous randomised control trials with objective patient-centred primary outcomes are required to establish evidence-based guidelines.